The estimated Net Worth of Jaume Pons is at least 11.6 百万$ dollars as of 14 August 2024. Dr Pons owns over 1,937 units of ALX Oncology stock worth over 1,289,492$ and over the last 4 years he sold ALXO stock worth over 9,029,264$. In addition, he makes 1,280,467$ as Pres、 CEO & Director at ALX Oncology.
Dr has made over 22 trades of the ALX Oncology stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 1,937 units of ALXO stock worth 4,997$ on 14 August 2024.
The largest trade he's ever made was selling 50,000 units of ALX Oncology stock on 16 April 2024 worth over 710,000$. On average, Dr trades about 12,991 units every 48 days since 2020. As of 14 August 2024 he still owns at least 591,510 units of ALX Oncology stock.
You can see the complete history of Dr Pons stock trades at the bottom of the page.
Dr. Jaume Pons Ph.D. is the Pres, CEO & Director at ALX Oncology.
As the Pres、 CEO & Director of ALX Oncology, the total compensation of Dr D at ALX Oncology is 1,280,467$. There are no executives at ALX Oncology getting paid more.
Dr D is 55, he's been the Pres、 CEO & Director of ALX Oncology since . There are 4 older and 3 younger executives at ALX Oncology. The oldest executive at ALX Oncology Holdings Inc. is Dr. Corey S. Goodman Ph.D., 70, who is the Independent Exec. Chairman.
Jaume's mailing address filed with the SEC is C/O ALX ONCOLOGY HOLDINGS INC., 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 4 years, insiders at ALX Oncology have traded over 32,891,459$ worth of ALX Oncology stock and bought 1,414,400 units worth 27,854,124$ . The most active insiders traders include G. Walmsley Graham、Jack Nielsen、Capital Ix, Llc Vivo Capita.... On average, ALX Oncology executives and independent directors trade stock every 22 days with the average trade being worth of 89,694$. The most recent stock trade was executed by Shelly Pinto on 14 August 2024, trading 564 units of ALXO stock currently worth 1,455$.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer. The company's pre-clinical products include SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was incorporated in 2015 and is based in Burlingame, California.
ALX Oncology executives and other stock owners filed with the SEC include: